ライフサイエンスコーパス: phototherapy

1 nonsystemic treatment (topical therapies or phototherapy).

2 tions in photocatalysis, nanoelectronics and phototherapy.

3 to undergo either aggressive or conservative phototherapy.

4 hotoadaptation for the dosimetry of UV-based phototherapy.

5 ne growth retardation who did not respond to phototherapy.

6 It may be prescribed in conjunction with phototherapy.

7 rse angiographic outcomes were attributed to phototherapy.

8 duction may eventually decrease the need for phototherapy.

9 thermore, these mice did not benefit from UV phototherapy.

10 lization; and (4) at least 1 readmission for phototherapy.

11 processes and image-guided precise conformal phototherapy.

12 utaneous GVHD with narrowband UV-B (NB UV-B) phototherapy.

13 ppressants, extracorporeal photopheresis, or phototherapy.

14 /DVDMS nanotheranostics (nanoDVD) for cancer phototherapy.

15 age Ib) disease and began ultraviolet (UV) B phototherapy.

16 to filtered sunlight and 223 to conventional phototherapy.

17 ter clobetasol treatment but not after UV-A1 phototherapy.

18 ces with gender, apneic spells, jaundice, or phototherapy.

19 emitting MS were treated with narrowband UVB phototherapy.

20 ate compared with treatment with oral agents/phototherapy.

21 n combination with narrowband UV-B (NB-UV-B) phototherapy.

22 mization of laser parameters for nondamaging phototherapy.

23 find broad applications in biotechnology and phototherapy.

24 ne was significantly reduced with aggressive phototherapy.

25 (66%, mostly anti-tumor necrosis factor) and phototherapy (15%) (P < .001).

26 After 1 month of NB-UV-B phototherapy, 16 mg of afamelanotide was administered su

27 The patient was initiated on NB UV-B phototherapy 3 times per week, resulting in clinically s

28 The effect of lung phototherapy administered during CO poisoning was also s

29 Phototherapy administered during severe CO poisoning lim

30 Only 7% of phototherapy-affected MVPs (150 out of 2,108) correlate

31 0 times over single treatment with SN-38 and phototherapy alone, respectively.

32 from 12 patients undergoing narrow-band UVB phototherapy and 12 corresponding healthy controls revea

33 the rates of death were 13% with aggressive phototherapy and 14% with conservative phototherapy for

34 rowband UV-B monotherapy vs combined NB-UV-B phototherapy and afamelanotide.

35 physical properties well-suited for clinical phototherapy and cancer imaging.

36 Rates of death in the aggressive-phototherapy and conservative-phototherapy groups were 2

37 months) who were candidates for systemic or phototherapy and had a Psoriasis Area and Severity Index

38 Studies have found that phototherapy and/or neonatal jaundice may be associated

39 Beyond their use in drug/gene delivery, phototherapy, and bioimaging, recent studies have reveal

40 uated, as compared with 90% for conventional phototherapy, and had a higher mean level of irradiance

41 lophosphamide, long-wavelength ultraviolet A phototherapy, and monoclonal antibodies such as denileuk

42 and include biological and cytotoxic drugs, phototherapy, and monoclonal antibodies that are directe

43 osuppressive/chemotherapeutic interventions, phototherapy, and other means.

44 e incidence of MI in the TNF inhibitor, oral/phototherapy, and topical cohorts were 3.05, 3.85, and 6

45 y and efficacy as compared with conventional phototherapy are unknown.

46 pare narrow-band UVB, UVA, and visible light phototherapy as second-line, adjunctive treatments in ad

47 Aggressive phototherapy, as compared with conservative phototherapy

48 .5%; 95% CI, 4.7%-6.1%) and readmissions for phototherapy by 53% (absolute risk reduction, 1.8%; 95%

49 When used in conjunction with phototherapy, calcitriol ointment should be applied afte

50 other systemic agents or phototherapy (oral/phototherapy cohort), and 5075 were not treated with TNF

51 acitretin combination, and then biologic and phototherapy combination.

52 apy group monthly for 4 months while NB-UV-B phototherapy continued; the other group continued to rec

53 trate that the combination of gene, drug and phototherapy delivered through a prophylactic hydrogel p

54 Noninvasive transesophageal phototherapy delivered to murine lungs via an optical fi

55 thoracotomy, we assessed the effect of lung phototherapy delivered to murine lungs via an optical fi

56 Subthreshold retinal phototherapy demonstrated clinical efficacy for the trea

57 Aggressive phototherapy did not significantly reduce the rate of de

58 Aggressive phototherapy did reduce rates of neurodevelopmental impa

59 Phototherapy during birth hospitalizations was reduced b

60 my of Pediatrics phototherapy threshold; (3) phototherapy during the birth hospitalization; and (4) a

61 e psoriasis who used systemic medications or phototherapy for at least 3 months from December 1, 1990

62 iasis in children, narrow band ultraviolet B phototherapy for atopic dermatitis and psoriasis, use of

63 ssive phototherapy and 14% with conservative phototherapy for infants with a birth weight of 751 to 1

64 in the delayed cord clamping groups required phototherapy for jaundice.

65 recalcitrant lesions in more severe disease; phototherapy for moderate disease; and systemic agents i

66 Future development and scaling up of lung phototherapy for patients with CO exposure may provide a

67 b, etanercept, infliximab, or ustekinumab or phototherapy for psoriasis.

68 ered sunlight was compared with conventional phototherapy for the treatment of hyperbilirubinemia in

69 ates on living systems, and lead to clinical phototherapy for the treatment of infections.

70 red sunlight was noninferior to conventional phototherapy for the treatment of neonatal hyperbilirubi

71 port describes the successful use of NB UV-B phototherapy for the treatment of sclerotic chronic cuta

72 practice of phototesting prior to commencing phototherapy, for therapeutic failure in sites such as t

73 the aggressive-phototherapy and conservative-phototherapy groups were 24% and 23%, respectively (rela

74 Enhancements in topical therapy and phototherapy have also increased the armamentarium of tr

75 ) or more in 10 newborns; treatment involved phototherapy in 136 cases and exchange transfusion in 5.

76 ious infection compared with retinoid and/or phototherapy in adults.

77 thylation pattern was reversed at the end of phototherapy in patients showing excellent clinical impr

78 ilirubin levels and childhood asthma without phototherapy intervention in the Collaborative Perinatal

79 use of filtered sunlight for the purpose of phototherapy is a safe and efficacious method for reduci

80 Phototherapy is an effective treatment, but a drug thera

81 The efficacy of photosensitizers in cancer phototherapy is often limited by photobleaching, low tum

82 burden in areas where effective conventional phototherapy is unavailable.

83 The long-term safety of narrowband UVB phototherapy is uncertain.

84 Narrowband UV-B (NB-UV-B) phototherapy is used extensively to treat vitiligo.

85 Late Impact of Getting Hyperbilirubinemia or Phototherapy (LIGHT) birth cohort.

86 gics, such as etanercept or adalimumab, with phototherapy likely results in greater reduction in dise

87 UV-A1 phototherapy may be a promising alternative treatment op

88 UV-A1 phototherapy may be considered a potential second-line t

89 soriasis, and open studies suggest that this phototherapy might improve atopic eczema.

90 The most frequently used phototherapy modality is UV-B, whereas methotrexate is t

91 The utility of these molecules for phototherapy of cancer is confirmed by the drastic incre

92 In CO-poisoned mice, phototherapy of exposed lungs at 532, 570, 592, and 628

93 which may underlie the beneficial effect of phototherapy on psoriasis.

94 ess the effects of direct lung illumination (phototherapy) on the CO elimination rate.

95 When treated with phototherapy or exchange transfusion, total serum biliru

96 portion of patients developed erythema after phototherapy or had a flare in their eczema sufficient t

97 vere plaque psoriasis who are candidates for phototherapy or systemic therapy.

98 (PDT), also known as photoradiation therapy, phototherapy, or photochemotherapy, involves the use of

99 naive and received other systemic agents or phototherapy (oral/phototherapy cohort), and 5075 were n

100 evaluated therapies combining biologics with phototherapy, oral medications, or other biologic agents

101 ments used for moderate-to-severe psoriasis (phototherapy, oral systemic, or biologic therapies) were

102 ht and in 1% of those receiving conventional phototherapy (P<0.001), but no infant met the criteria f

103 and 35.6% [95% CI, 18.2% to 53.1%] for UV-A1 phototherapy [P = .006]).

104 or medium-dose UV-A1 (50 J/cm(2)) home-based phototherapy, performed 4 times weekly for 3 months.

105 clonal antibody (mAb)-based, highly specific phototherapy (photoimmunotherapy; PIT) that uses a near

106 apies which include topical corticosteroids, phototherapy (psoralen with UVA or UVB), topical chemoth

107 We assessed the safety and tolerability of phototherapy (PT) with MLu in patients undergoing percut

108 Phototherapy (PT), a light activated treatment modality,

109 nalysis, it was observed that treatment with phototherapy (rate ratio [RR], 1.09 [95% CI, 0.62-1.93];

110 nlight exposure and when determining optimal phototherapy regimens.

111 al impairment (26%, vs. 30% for conservative phototherapy; relative risk, 0.86; 95% CI, 0.74 to 0.99)

112 ination of afamelanotide implant and NB-UV-B phototherapy resulted in clinically apparent, statistica

113 MS patients treated with UVB phototherapy showed an increase in induced Tregs and tol

114 phototherapy, as compared with conservative phototherapy, significantly reduced the mean peak serum

115 Three trials on systemic therapy/phototherapy suggested that induction of remission resul

116 ily treated with exposure to blue light, and phototherapy systems have been developed for low-resourc

117 d here utilizes the 48-year-old mechanism of phototherapy that is commonly implemented in the treatme

118 After UV-A1 phototherapy, the VAS score for burning and/or pain (MD,

119 or above the American Academy of Pediatrics phototherapy threshold.

120 exceeding the American Academy of Pediatrics phototherapy threshold; (3) phototherapy during the birt

121 of nanoDVD are shown to be synergistic with phototherapy to improve antitumor efficacy in vitro and

122 The resulting jaundice may be managed with phototherapy to isomerize the biosynthetic 4Z,15Z-biliru

123 Current therapy relies on phototherapy to prevent kernicterus, but liver transplan

124 It is unclear whether aggressive phototherapy to prevent neurotoxic effects of bilirubin

125 TNF inhibitors, other systemic therapies, or phototherapy (topical cohort).

126 Descriptive study comparing TSB levels and phototherapy use before and after recalibration at Kaise

127 lamp types appear to be of similar efficacy, phototherapy using a selective broadband source may be a

128 Phototherapy was administered twice a week for 12 weeks.

129 in a significant clinical improvement, UV-A1 phototherapy was inferior to the current gold standard t

130 cohort study of infants born at a time when phototherapy was unavailable, neonatal hyperbilirubinemi

131 ours of age who received at least 5 hours of phototherapy; we prespecified a noninferiority margin of

132 including the development of erythema during phototherapy, were similar for the two lamp types.

133 Phototherapy with UV light is a standard treatment for p